ClinicalTrials.gg
CompletedNCT05844995Updated Mar 15, 2024

A Study of Acetaminophen/Naproxen Sodium Fixed Combination Tablets in Adolescents 12 to <17 Years of Age With Pain

A Phase 1 interventional study of Acetaminophen/Naproxen Sodium in Orthodontic Pain, sponsored by Johnson & Johnson Consumer Inc. (J&JCI). Completed at 1 site in United States. Open to participants aged 12 Years to 16 Years, including healthy volunteers. Per ClinicalTrials.gov, last updated 2024-03-15.

Sponsored by Johnson & Johnson Consumer Inc. (J&JCI) (formerly part of Johnson & Johnson) · Phase 1, Interventional, and Other

From the registry’s dates

  • Primary completion was Feb 2024, 2 years 9 months ago, and no results have been posted to the registry.

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 1
Study type
Interventional
Enrollment
24
Allocation
Not applicable
Ages
12 Years to 16 Years
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-17

Among 137 studies testing acetaminophen in Pain — 5 open to participants now, 5 under way, none of them phase 3. Acetaminophen · Pain.

Enrollment
116th of 137
24 · median 95
Started
2023
with 2 others
Phase 1
11 of 137
none open now
Registered
126th of 137
by date

Among the 137 studies testing acetaminophen in Pain, this one is the 116th largest by enrollment, is one of 3 that started in 2023, is one of 11 in phase 1, and was the 126th registered.

Pain

10,069 studies on the registry are indexed under Pain; 1,650 are open to participants now.

Browse Pain studies →

Open to participants now

5 of the 137 studies testing acetaminophen in Pain are open now, in 3 countries. Recruiting first, the newest first:

By country, each count listing its studies:

All 5 open studies →

About acetaminophen

Acetaminophen: first FDA approval 1968 (NEOPAP). What it is approved for, and how studies give it, is on its page →

Who these studies take

Of the 927 Pain studies recruiting now, 382 (41%) set no upper age limit and 434 (47%) stop at 75 or younger; 146 take children under 18; 221 take healthy volunteers.

This study: 12 Years to 16 Years · all sexes · healthy volunteers too.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 137 studies testing acetaminophen in Pain, or all of them as a file.
02

Study summary

The purpose of this study is to investigate the population pharmacokinetics of acetaminophen and naproxen from a novel acetaminophen /naproxen sodium fixed combination tablet in adolescents 12 to less than (\<) 17 years of age with post-procedure orthodontic pain and to describe the effect of subject-specific covariates, including age and body weight, on inter-subject variability in acetaminophen and naproxen pharmacokinetics in adolescents 12 to \<17 years of age with post-procedure orthodontic pain.

03

Conditions studied

  • Orthodontic Pain

Browse trials for

04

Who can participate

Ages eligible
12 Years to 16 Years
Sexes eligible
All
Accepts healthy volunteers
Yes

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • A parent or a legal guardian of the participant has signed and dated the document and a written assent has been signed by the participant
  • Has undergone an orthodontic procedure within 72 hours prior to dosing
  • Is otherwise a healthy adolescent between the ages of 12 to less than (\<) 17 years at baseline (dosing). Health is defined as the absence of abnormalities as judged by the principle investigator (PI) on the basis of a detailed medical history, physical examination, blood pressure, respiratory rate and pulse rate measurements, and clinical laboratory tests. The responsible PI may request additional investigations or analyses if necessary
  • Has a minimum weight of 72 pounds and has a (BMI) between the 5th and 95th percentile for their age at dosing
  • Has been fasted for at least 10 hours prior to dose administration of the product
  • Is a non-tobacco user or previous user who completely stopped smoking or using any form of tobacco or nicotine-containing product [including e-cigarettes, cigarettes, non-combusted cigarettes, cigars, smokeless tobacco (such as dip, snuff, snus, and chewing tobacco)] for at least 12 months before screening visit of this study
  • If female, have a negative test for pregnancy at screening and baseline (dosing)
  • Females of and males agree to the requirements
  • Is able to comprehend the requirements of the study (based upon clinical site personnel's assessment) and is willing and able to comply with scheduled visits, treatment plan, laboratory tests, and other study procedures specified within the protocol
  • Are willing for investigational product of this study to be the only analgesic product used during the study

Exclusion criteria

Exclusion Criteria:

  • Use of prescription or non-prescription medications within a period less than 5 half-lives before the first product (IP) administration unless these are or occasional use of other medications approved by the Investigator
  • Use of Ibuprofen within 6 hours prior to the dose administration of the investigational product
  • Use of any vitamins, dietary and herbal supplements within seven days before first dose of study drug
  • Has to acetaminophen, naproxen, other non-steroidal anti-inflammatory drug (NSAIDs), including acetylsalicylic acid, or to any of the ingredients
  • If female, has a positive pregnancy test or is breast-feeding or currently trying to become pregnant
  • Has a positive test for (HIV) 1 and 2 antibodies, surface antigen (HBsAg), or antibodies (anti-HCV)
  • Has a positive test for drugs of abuse at screening or baseline (dosing)
  • Has difficult venipuncture access and/or refuses to undergo venipuncture
  • Has renal or hepatic impairment according to the medically qualified Investigator discretion, or presence of a disease, which in the opinion of the Investigator, would preclude the use of IP
  • Has a history of peptic ulcers, gastrointestinal bleeding of any etiology, bleeding disorders, gastrointestinal disease (including chronic heartburn or gastroesophageal reflux disease, or any other active inflammatory disease of the gastrointestinal tract such as ulcerative colitis or crohn's disease), or has a history of gastrointestinal surgery (including cholecystectomy) that would affect the pharmacokinetic (PK) assessment of the drug or the safety of the participant
  • Has history of substance abuse, as judged by the PI, within 12 months preceding this study
  • Has used alcohol within 24 hours of baseline visit and/or has positive alcohol test in expired air at screening or baseline visit
  • Has used food or beverages containing xanthines (that is, tea, coffee, cola drinks, energy drinks or chocolate) for 48 hours prior to the dosing and during the study period
  • Has used grapefruit and savoy oranges for 48 hours prior to the dosing and during the study period
  • Participating in a clinical trial and/or treated with any investigational product within 3 months preceding the dose of study drug
  • Has preplanned surgery, procedures, or personal commitments that would interfere with the conduct of the study
  • Had an acute blood loss of 50 milliliter (mL) to 249 mL within the 30 days, or 250 mL to 449 mL within the 45 days, or greater than or equal to (>=) 450 mL within the 60 days before first dose administration
  • Has any acute or chronic medical or psychiatric condition(s) that may increase the risk associated with study participation or IP administration or may interfere with the interpretation of study results and, in the judgment of the medically qualified Investigator, would make the participant inappropriate for entry into this study
  • Has any clinically important abnormal value for serum chemistry, hematology, or urinalysis at screening. Laboratory values will generally be within the normal ranges, although minor deviations in tests (except those explicitly specified in the inclusion criteria) that are not considered clinically important by the Investigator are acceptable
  • Is related to persons involved directly or indirectly with the conduct of the study (that is, principal investigator, sub-investigators, study coordinators, other study personnel, employees or contractors of the Sponsor or Johnson \& Johnson (J\&J) subsidiaries, and the family of each)
Terms in these criteria, in plain language(10)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Informed consent

Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.

You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.

Clinically significant

Judged by the study doctor to matter for your health or for the study. It is a doctor’s decision, so ask the study team if you are unsure whether something counts.

BMI (body mass index)

Weight in kilograms divided by height in metres squared. Example: 70 kg and 1.75 m gives 70 ÷ (1.75 × 1.75) ≈ 22.9.

What counts as overweight or obesity differs between countries (some use lower cut-offs), so go by the range the study states.

Investigational drug or device

A drug or device being studied in a clinical trial.

It may be new, or already approved and being studied for another use, dose or form. Criteria often leave out people who took part in another study of one within a recent period, commonly 30 days or five half-lives.

Childbearing potential

Able to become pregnant: from the first period until menopause, unless permanently unable to through surgery (removal of the womb, or of both ovaries or both fallopian tubes).

Criteria for people of childbearing potential usually ask for a negative pregnancy test and for contraception during the study and for a time after it.

Contraception

Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.

Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.

Hypersensitivity

An allergy, or another reaction of the immune system, to a substance. “Hypersensitivity to the study drug” means a known allergic reaction to it — not every side effect a medicine can have.

HIV

The human immunodeficiency virus, which weakens the immune system.

Many studies now accept people whose HIV is controlled on treatment, judged by the viral load and the CD4 count. Check the limits this study sets.

Hepatitis B tests

Hepatitis B is a virus that infects the liver. These are separate tests: HBsAg positive usually means a current infection (a recent vaccination can briefly cause it too); total anti-HBc (HBcAb) positive means an infection now or in the past; HBV DNA measures how much virus is in the blood.

Some studies accept a past infection if HBV DNA is undetectable, sometimes with antiviral medicine during the study. Check what this study allows.

Hepatitis C tests

Hepatitis C is a virus that infects the liver. An HCV antibody test can stay positive after an infection has cleared (and is occasionally positive without one); an HCV RNA test shows whether the virus is there now.

After treatment, hepatitis C counts as cured when HCV RNA is still undetectable 12 weeks or more after the treatment ended. Studies often accept people cured this way.

05

Study design

Phase
Phase 1
Primary purpose
Other
Allocation
Not applicable
Intervention model
Single group
Masking
None (open label)
Enrollment
24 participants (actual)

Study arms

  • Experimental
    Acetaminophen /Naproxen Sodium

    Participants with age group 12 to less than (\<) 17 years who undergone a non-surgical orthodontic procedure will enroll and receive fixed dose combination of acetaminophen/naproxen sodium tablet orally on baseline (Day 0).

    Drug: Acetaminophen/Naproxen Sodium

Interventions

  • DrugAcetaminophen/Naproxen Sodium

    Drug pages: Acetaminophen · Naproxen

    Fixed dose combination of acetaminophen/naproxen sodium tablet will be administered orally.

06

What researchers measure

Primary outcomes

  1. Apparent Clearance (CL/F) of Acetaminophen/Naproxen Sodium

    CL/F is defined as apparent clearance of acetaminophen/naproxen sodium.

    Time frame: Pre-dose up to 48 hours post dose

  2. Apparent Central Volume of Distribution (Vc/F) After Oral Dosing of Acetaminophen/Naproxen Sodium

    Vc/F is defined as apparent central volume of distribution after oral dosing of acetaminophen/naproxen sodium.

    Time frame: Pre-dose up to 48 hours post dose

  3. Apparent Peripheral Volume of Distribution (Vp/F) After Oral Dosing of Acetaminophen/Naproxen Sodium

    Vp/F is defined as apparent peripheral volume of distribution after oral dosing of acetaminophen/naproxen sodium.

    Time frame: Pre-dose up to 48 hours post dose

  4. Apparent Inter-compartmental Clearance (Q/F) of Acetaminophen/Naproxen Sodium

    Q/F is defined as apparent inter-compartmental clearance of acetaminophen/naproxen sodium.

    Time frame: Pre-dose up to 48 hours post dose

  5. First-order Absorption Rate Constant (Ka) of Acetaminophen/Naproxen Sodium

    Ka is defined as first-order absorption rate constant of acetaminophen/naproxen sodium.

    Time frame: Pre-dose up to 48 hours post dose

  6. Maximum Plasma Concentration (Cmax) of Acetaminophen/Naproxen Sodium

    Cmax is defined as maximum plasma concentration of acetaminophen/naproxen sodium.

    Time frame: Pre-dose up to 48 hours post dose

  7. Time of occurrence of Maximum Plasma Concentration (Tmax) of Acetaminophen/Naproxen Sodium

    Tmax is defined as time of occurrence of maximum plasma concentration of acetaminophen/naproxen sodium.

    Time frame: Pre-dose up to 48 hours post dose

  8. Area Under the Plasma Concentration versus Time Curve from Start of Drug Administration Until the Time of the Last Measurable Plasma Concentration (AUC[0-t])

    AUC(0-t) is defined as area under the plasma concentration versus time curve from start of drug administration until the time of the last measurable plasma concentration of acetaminophen/naproxen sodium.

    Time frame: Pre-dose up to 48 hours post dose

  9. Area Under the Plasma Concentration versus Time Curve From Start of Drug Administration Until Infinity (AUC[0-infinite])

    AUC(0-infinite) is defined as area under the plasma concentration versus time curve from start of drug administration until infinity of acetaminophen/naproxen sodium.

    Time frame: Pre-dose up to 48 hours post dose

  10. Terminal Elimination Rate Constant (lambda[z]) of Acetaminophen/Naproxen Sodium

    Lambda(z) is defined as terminal elimination rate constant of acetaminophen/naproxen sodium.

    Time frame: Pre-dose up to 48 hours post dose

  11. Half Life (t1/2) of Acetaminophen/Naproxen Sodium

    T1/2 is defined as half life of acetaminophen/naproxen sodium.

    Time frame: Pre-dose up to 48 hours post dose

Secondary outcomes

  1. Number of Participants with Adverse Events (AEs)

    An AE is any untoward medical occurrence that occurs in participants after they have signed an informed consent for the study. The event does not need to have a suspected causal relationship with the investigational product (IP).

    Time frame: Up to 3 days

07

Study locations

1 site
  • JBR Clinical Research LLP
    Salt Lake City, Utah 84107, United States
08

References and documents

Publications

  • World Medical Association. World Medical Association Declaration of Helsinki: ethical principles for medical research involving human subjects. JAMA. 2013 Nov 27;310(20):2191-4. doi: 10.1001/jama.2013.281053. No abstract available. PubMed 24141714 ↗
  • GUZMAN F, BRAUN C, LIM RK, POTTER GD, RODGERS DW. NARCOTIC AND NON-NARCOTIC ANALGESICS WHICH BLOCK VISCERAL PAIN EVOKED BY INTRA-ARTERIAL INJECTION OF BRADYKININ AND OTHER ALGESIC AGENTS. Arch Int Pharmacodyn Ther. 1964 Jun 1;149:571-88. No abstract available. PubMed 14191090 ↗
  • LIM RK, GUZMAN F, RODGERS DW, GOTO K, BRAUN C, DICKERSON GD, ENGLE RJ. SITE OF ACTION OF NARCOTIC AND NON-NARCOTIC ANALGESICS DETERMINED BY BLOCKING BRADYKININ-EVOKED VISCERAL PAIN. Arch Int Pharmacodyn Ther. 1964 Nov 1;152:25-58. No abstract available. PubMed 14248351 ↗
  • Aronoff DM, Oates JA, Boutaud O. New insights into the mechanism of action of acetaminophen: Its clinical pharmacologic characteristics reflect its inhibition of the two prostaglandin H2 synthases. Clin Pharmacol Ther. 2006 Jan;79(1):9-19. doi: 10.1016/j.clpt.2005.09.009. No abstract available. PubMed 16413237 ↗
  • Pickering G, Loriot MA, Libert F, Eschalier A, Beaune P, Dubray C. Analgesic effect of acetaminophen in humans: first evidence of a central serotonergic mechanism. Clin Pharmacol Ther. 2006 Apr;79(4):371-8. doi: 10.1016/j.clpt.2005.12.307. PubMed 16580905 ↗
  • Mallet C, Daulhac L, Bonnefont J, Ledent C, Etienne M, Chapuy E, Libert F, Eschalier A. Endocannabinoid and serotonergic systems are needed for acetaminophen-induced analgesia. Pain. 2008 Sep 30;139(1):190-200. doi: 10.1016/j.pain.2008.03.030. Epub 2008 May 15. PubMed 18485596 ↗
  • McGilveray IJ, Mattok GL, Fooks JR, et al. Acetaminophen II: A comparison of the physiological availabilities of different commercial dosage forms. Can J Pharmaceut Sci 1971;6:38-42.
  • Liu DJ, Collaku A, Youngberg SP. Bioavailability and pharmacokinetic profile of a newly-developed twice-a-day sustained-release paracetamol formulation. Int J Clin Pharmacol Ther. 2015 Feb;53(2):172-81. doi: 10.5414/CP202146. PubMed 25500485 ↗
  • Paracetamol. In: Sweetman S, ed. Martindale - The Complete Drug Reference. London, UK: The Pharmaceutical Press. 37th ed. 2011:76-79.
  • Grosser T, Smyth E, FitzGerald. Anti-Inflammatory, Antipyretic, and Analgesic Agents; Pharmacotherapy of Gout. In: Goodman LS, Brunton LL, Chabner B, Knollman BC. Goodman and Gilman's The Pharmacological Basis of Therapeutics. 12th ed. New York, McGraw-Hill. 2011:959- 1004.
  • McNeil Consumer & Specialty Pharmaceuticals Clinical Pharmacology Report for Protocol 02- 161: Tolerability and multiple-dose pharmacokinetics of acetaminophen (paracetamol) at and above the currently recommended dose. Fort Washington, PA. McNeil Consumer & Specialty Pharmaceuticals Company. Aug 2005.
  • McNeil Consumer Products Company Statistical Report 7: Interim statistical analysis of the study of the bioavailability and antipyretic effectiveness of acetaminophen in children. Fort Washington, PA. McNeil Consumer Products Company. Dec 1978. [Meta-Analysis Code P00102]
  • McNeil Consumer Products Company Statistical Report 65 for Protocol 0-220: A double-blind multiple-dose study of the comparative antipyretic effectiveness and safety of standard and double standard doses of acetaminophen in febrile children. Fort Washington, PA. McNeil Consumer Products Company. Jun 1986. [Meta-Analysis Code P80220]
  • McNeil Protocol 2-227 Data Listings. A double-blind study of the comparative antipyretic effectiveness and safety of a single 15 mg/kg, 30 mg/kg or 40 mg/kg dose of acetaminophen. Oct 1982 [Meta-Analysis Code P82227]
  • McNeil Consumer Products Company Report for Protocol 93-308: Pharmacokinetic and pharmacodynamic modeling of acetaminophen in febrile children: Evaluation of three products. Fort Washington, PA. McNeil Consumer Products Company. 1994. [Meta-Analysis Code P93308]
  • McNeil Consumer Products Company Data Listings for Protocol 1-224: A double-blind study of the comparative antipyretic effectiveness and safety of a single 10 mg/kg, 20 mg/kg or 30 mg/kg dose of acetaminophen. Sep 1981. [Meta-Analysis Code P81224]
  • Ji P, Wang Y, Li Z, Doddapaneni S, Hertz S, Furness S, Sahajwalla CG. Regulatory review of acetaminophen clinical pharmacology in young pediatric patients. J Pharm Sci. 2012 Dec;101(12):4383-9. doi: 10.1002/jps.23331. Epub 2012 Oct 16. PubMed 23073837 ↗
  • Wilson JT, Brown RD, Bocchini JA Jr, Kearns GL. Efficacy, disposition and pharmacodynamics of aspirin, acetaminophen and choline salicylate in young febrile children. Ther Drug Monit. 1982;4(2):147-80. doi: 10.1097/00007691-198206000-00003. No abstract available. PubMed 6980501 ↗
  • Levy G. Comparative pharmacokinetics of aspirin and acetaminophen. Arch Intern Med. 1981 Feb 23;141(3 Spec No):279-81. doi: 10.1001/archinte.141.3.279. PubMed 7469620 ↗
  • Milligan TP, Morris HC, Hammond PM, Price CP. Studies on paracetamol binding to serum proteins. Ann Clin Biochem. 1994 Sep;31 ( Pt 5):492-6. doi: 10.1177/000456329403100512. PubMed 7832576 ↗
  • Forrest JA, Clements JA, Prescott LF. Clinical pharmacokinetics of paracetamol. Clin Pharmacokinet. 1982 Mar-Apr;7(2):93-107. doi: 10.2165/00003088-198207020-00001. PubMed 7039926 ↗
  • Paracetamol In: Dollery C., editor. Therapeutic drugs. 2nd ed. Vol 2. Edinburgh: Churchill Livingstone. 1999
  • Peterson RG, Rumack BH. Pharmacokinetics of acetaminophen in children. Pediatrics. 1978 Nov;62(5 Pt 2 Suppl):877-9. PubMed 364399 ↗
  • Davies NM, Anderson KE. Clinical pharmacokinetics of naproxen. Clin Pharmacokinet. 1997 Apr;32(4):268-93. doi: 10.2165/00003088-199732040-00002. PubMed 9113437 ↗
  • Product Monograph for Aleve (Naproxen Sodium Tablets USP/Liquid Gels/Capsules 220 mg). Bayer Inc. Consumer Care. Revised January 8th, 2015.
  • Todd PA, Clissold SP. Naproxen. A reappraisal of its pharmacology, and therapeutic use in rheumatic diseases and pain states. Drugs. 1990 Jul;40(1):91-137. doi: 10.2165/00003495-199040010-00006. PubMed 2202585 ↗
  • Segre EJ. Naproxen sodium (Anaprox): pharmacology, pharmacokinetics and drug interactions. J Reprod Med. 1980 Oct;25(4 Suppl):222-5. PubMed 7001021 ↗
  • Sevelius H, Runkel R, Segre E, Bloomfield SS. Bioavailability of naproxen sodium and its relationship to clinical analgesic effects. Br J Clin Pharmacol. 1980 Sep;10(3):259-63. doi: 10.1111/j.1365-2125.1980.tb01753.x. PubMed 7437243 ↗
  • Setiawati S et al. Bioequivalence study with two naproxen sodium tablet formulations in healthy subjects. J Bioequival Availab 2009;1: 28-33.
  • Inc., P., PRODUCT MONOGRAPH, PEDIAPHARM NAPROXEN SUSPENSION, naproxen, 25 mg/mL Suspension, USP, Non-Steroidal Anti-Inflammatory Drug (NSAID) 2018.
  • Valitalo P, Kumpulainen E, Manner M, Kokki M, Lehtonen M, Hooker AC, Ranta VP, Kokki H. Plasma and cerebrospinal fluid pharmacokinetics of naproxen in children. J Clin Pharmacol. 2012 Oct;52(10):1516-26. doi: 10.1177/0091270011418658. Epub 2011 Nov 8. PubMed 22067196 ↗
  • Altman RD. A rationale for combining acetaminophen and NSAIDs for mild-to-moderate pain. Clin Exp Rheumatol. 2004 Jan-Feb;22(1):110-7. PubMed 15005014 ↗
  • Ong CK, Seymour RA, Lirk P, Merry AF. Combining paracetamol (acetaminophen) with nonsteroidal antiinflammatory drugs: a qualitative systematic review of analgesic efficacy for acute postoperative pain. Anesth Analg. 2010 Apr 1;110(4):1170-9. doi: 10.1213/ANE.0b013e3181cf9281. Epub 2010 Feb 8. PubMed 20142348 ↗
  • Mehlisch DR, Aspley S, Daniels SE, Southerden KA, Christensen KS. A single-tablet fixed-dose combination of racemic ibuprofen/paracetamol in the management of moderate to severe postoperative dental pain in adult and adolescent patients: a multicenter, two-stage, randomized, double-blind, parallel-group, placebo-controlled, factorial study. Clin Ther. 2010 Jun;32(6):1033-49. doi: 10.1016/j.clinthera.2010.06.002. PubMed 20637958 ↗
  • Palma-Aguirre JA, Villalpando-Hernandez J, Novoa-Heckel G, Oliva I, Carino L, Lopez-Bojorquez E, Burke-Fraga V, Namur S, Gonzalez-de la Parra M. Bioavailability of two oral-tablet and two oral-suspension formulations of naproxen sodium/paracetamol (acetaminophen): single-dose, randomized, open-label, two-period crossover comparisons in healthy Mexican adult subjects. Clin Ther. 2009 Feb;31(2):399-410. doi: 10.1016/j.clinthera.2009.02.002. PubMed 19302912 ↗
  • Topolski F, Moro A, Correr GM, Schimim SC. Optimal management of orthodontic pain. J Pain Res. 2018 Mar 16;11:589-598. doi: 10.2147/JPR.S127945. eCollection 2018. PubMed 29588616 ↗
  • Cheng C, Xie T, Wang J. The efficacy of analgesics in controlling orthodontic pain: a systematic review and meta-analysis. BMC Oral Health. 2020 Sep 18;20(1):259. doi: 10.1186/s12903-020-01245-w. PubMed 32948150 ↗
  • Monk AB, Harrison JE, Worthington HV, Teague A. Pharmacological interventions for pain relief during orthodontic treatment. Cochrane Database Syst Rev. 2017 Nov 28;11(11):CD003976. doi: 10.1002/14651858.CD003976.pub2. PubMed 29182798 ↗
  • Krishnan V. Orthodontic pain: from causes to management--a review. Eur J Orthod. 2007 Apr;29(2):170-9. doi: 10.1093/ejo/cjl081. PubMed 17488999 ↗
  • Polat O, Karaman AI, Durmus E. Effects of preoperative ibuprofen and naproxen sodium on orthodontic pain. Angle Orthod. 2005 Sep;75(5):791-6. doi: 10.1043/0003-3219(2005)75[791:EOPIAN]2.0.CO;2. Erratum In: Angle Orthod. 2008 Nov;78(6):976. Angle Orthod. 2008 Sep;78(5):798. PubMed 16279825 ↗
  • Zarif Najafi H, Oshagh M, Salehi P, Babanouri N, Torkan S. Comparison of the effects of preemptive acetaminophen, ibuprofen, and meloxicam on pain after separator placement: a randomized clinical trial. Prog Orthod. 2015;16:34. doi: 10.1186/s40510-015-0104-y. Epub 2015 Oct 14. PubMed 26467790 ↗
  • Gritsiuk AI. [On the problem of the effect of prednisolone and salicylates on the fibrinolytic activity of the blood in patients with rheumatism]. Ter Arkh. 1967 Sep;39(9):60-1. No abstract available. Russian. PubMed 5611706 ↗
  • Harrington JT, Isner JM, Kassirer JP. Our national obsession with potassium. Am J Med. 1982 Aug;73(2):155-9. doi: 10.1016/0002-9343(82)90171-1. No abstract available. PubMed 7051823 ↗
  • Bernhardt MK, Southard KA, Batterson KD, Logan HL, Baker KA, Jakobsen JR. The effect of preemptive and/or postoperative ibuprofen therapy for orthodontic pain. Am J Orthod Dentofacial Orthop. 2001 Jul;120(1):20-7. doi: 10.1067/mod.2001.115616. PubMed 11455373 ↗
  • U.S. Department of Health and Human Services, Food and Drug Administration. Center for Drug Evaluation and Research (CDER); Center for Biologics Evaluation and Research (CBER). Population Pharmacokinetics, Guidance for Industry. (February 2022). https://www.fda.gov/regulatory-information/search-fda-guidance-documents/population-pharmacokinetics
  • U.S. Department of Health and Human Services, Food and Drug Administration. Center for Drug Evaluation and Research (CDER). General Clinical Pharmacology Considerations for Pediatric Studies of Drugs, Including Biological Products. Guidance for Industry (Draft). (September 2022). https://www.fda.gov/regulatory-information/search-fda-guidance-documents/general-clinical-pharmacologyconsiderations- pediatric-studies-drugs-including-biological-products
  • Wang Y, Jadhav PR, Lala M, Gobburu JV. Clarification on precision criteria to derive sample size when designing pediatric pharmacokinetic studies. J Clin Pharmacol. 2012 Oct;52(10):1601-6. doi: 10.1177/0091270011422812. Epub 2011 Dec 12. No abstract available. PubMed 22162537 ↗

Individual participant data

Plan to share: Yes — Johnson \& Johnson Consumer Inc. has an agreement with the Yale Open Data Access (YODA) Project to serve as the independent review panel for evaluation of requests for clinical study reports and participant level data from investigators and physicians for scientific research that will advance medical knowledge and public health. Requests for access to the study data can be submitted through the YODA Project site at http://yoda.yale.edu

Data sharing details ↗ · yoda.yale.edu

09

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Ran from Sep 2023 to primary completion in Feb 2024, 4 months.

Of 104 industry-sponsored phase 1 interventional studies under Pain, half reached primary completion within 4 months of starting (the median), counting those still running; a quarter within 1 and three quarters within 9. This study's 4 months is close to that.

Counting every sponsor, half of 220 studies reached it within 9 months; a quarter within 3 and three quarters within 29.

How these figures are worked out, and which studies are left out of them.

Registered
Apr 25, 2023
First posted
May 6, 2023
StartActual
Sep 13, 2023
Primary completionActual
Feb 12, 2024
CompletionActual
Feb 14, 2024
Last update
Mar 15, 2024
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Mar 15, 2024, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
10

Registry details

Key details

Study ID
NCT05844995
Responsible party
Sponsor
First posted
May 6, 2023
Start date
Sep 13, 2023
Primary completion
Feb 12, 2024
Completion
Feb 14, 2024
Last update
Mar 15, 2024

Study contacts

Johnson & Johnson Consumer Inc. (J&JCI) Clinical Trial
study director · Johnson & Johnson Consumer Inc. (J&JCI)

Oversight

Data monitoring committee
No
FDA-regulated drug
Yes
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is completed, as verified in Mar 2024. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drugs tested here: Acetaminophen · Naproxen

Start the discussion